Press release
IGC Pharma's (NYSE: IGC) CEO Appears on Bloomberg TV Discussing Alzheimer's Fast-Acting IGC-AD1 Pharmaceutical Therapeutic - More Stocks Inside
The company recently reported that enrollment in its Phase 2 CALMA clinical trial has reached approximately 80% of its target, marking a significant milestone as IGC advances one of its most closely watched Alzheimer's therapeutics programs. The company has also expanded its clinical site network and strengthened its intellectual property portfolio, including new patents tied to its proprietary AI-powered drug discovery platform and IGC-AD1. Listen To Full Interview Now! [https://www.youtube.com/watch?v=rNLeeu3v6S4&t=92s]
Alongside IGC Pharma (NYSE: IGC), investors are watching Volato Group, Inc. (NYSE: SOAR), Abits Group Inc. (Nasdaq: ABTS), HUB Cyber Security Ltd. (Nasdaq: HUBC), Hitek Global Inc. (Nasdaq: HKIT), and Kartoon Studios (NYSE: TOON) as these smallcap stocks under $1, high-volume momentum stocks remain active in early trading.
Beyond Alzheimer's agitation, IGC Pharma is developing additional programs targeting amyloid plaques, neurodegenerative disease, cognitive decline, precision medicine, and neuroscience innovation, positioning the company at the intersection of artificial intelligence and biotechnology.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.
Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=igc-pharmas-nyse-igc-ceo-appears-on-bloomberg-tv-discussing-alzheimers-fastacting-igcad1-pharmaceutical-therapeutic-more-stocks-inside]
Country: United States
Website: http://www.thestreetreports.com
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release IGC Pharma's (NYSE: IGC) CEO Appears on Bloomberg TV Discussing Alzheimer's Fast-Acting IGC-AD1 Pharmaceutical Therapeutic - More Stocks Inside here
News-ID: 4534327 • Views: …
More Releases from ABNewswire
GuardHouse Camera Reviews 2026: Expectations, Performance & Buyer Considerations
Home security has become a growing concern for millions of families worldwide. Rising cases of theft, burglary, and unauthorized intrusions mean that protecting loved ones and personal property is no longer optional, it is essential. Unfortunately, traditional security systems often come with high upfront costs, complicated installations, hidden monthly fees, and long-term contracts. For many homeowners and renters alike, these barriers make reliable home protection feel out of reach.
As a…
QuietLab Pro Reviews: Customer Feedback, Performance, Pros, Cons & User Consider …
QuietLab Pro Mouthpiece is an anti-snoring device designed to minimize snoring by improving airway openness during sleep. Quiet Lab Pro is loved by many customers because it is very effective and easy to adjust to any mouth size. Because of its success, many users have given QuietLab Pro a five-star rating for its comfort and reliability.
In this QuietLab Pro review, we will look closely at how it works, its special…
Halo Grow Reviews 2026: Features, HaloGrow Performance, Pros, Cons & Buyer Consi …
Every single morning, thousands of women look in the bathroom mirror and feel a quiet, heavy sense of heartbreak. Finding clumps of hair in your shower drain or watching your once-thick ponytail get thinner and thinner is completely exhausting. It steals your confidence and makes you feel helpless.
For a long time, the only real choices out there were incredibly frustrating. You either had to spend a fortune on expensive salon…
Rise and Grind With NecroBrew: The Alternative Coffee Brand Delivering Peak Fres …
NecroBrew is gaining momentum as the go-to coffee brand for drinkers who want freshly roasted beans without the generic branding. With every batch roasted to order and an unmistakable alternative identity, the company is proving there is strong demand for coffee that refuses to play it safe.
There is something undeniably ritual about making coffee. The grind, the pour, the aroma filling a room. For a growing number of coffee enthusiasts,…
More Releases for IGC
IGC Pharma (NYSE: IGC) Showcasing 7 AI Breakthroughs Advancing Alzheimer's Drug …
Image: http://www.abnewswire.com/pressreleases/wp-content/uploads/2026/07/2026
Artificial Intelligence is rapidly transforming drug discovery, clinical research, and Alzheimer's disease development, and IGC Pharma, Inc. (NYSE: IGC) is positioning itself at the forefront of that evolution. The clinical-stage biotechnology company will present seven scientific papers at the Alzheimer's Association International Conference (AAIC) 2026 in London, July 12-15, highlighting a growing portfolio of AI-powered healthcare technologies designed to accelerate Alzheimer's drug development, improve clinical trials, and enhance precision…
IGC Pharma (NYSE: IGC) CEO Discusses AI, Alzheimer's Drug Development and Key 20 …
Image: http://www.abnewswire.com/pressreleases/wp-content/uploads/2026/07/2026
Investors following the rapidly growing Alzheimer's disease, Artificial Intelligence (AI), and biotechnology sectors now have an opportunity to hear directly from IGC Pharma, Inc. (NYSE American: IGC) CEO Ram Mukunda in a new interview on The Street Reports Podcast, where he discusses the Company's clinical progress, AI initiatives, and long-term strategy.
During the interview, Mukunda highlights IGC Pharma's lead Phase 2 Alzheimer's drug candidate, IGC-AD1, which is being evaluated in…
IGC Pharma (NYSE: IGC) CEO and CFO Acquire More Than 4.2 Million Shares
IGC Pharma, Inc. (NYSE: IGC), a clinical-stage biotechnology company developing Alzheimer's disease therapeutics and AI-enabled healthcare technologies, disclosed in a Form 4 filing that two senior executives increased their ownership stakes through debt-for-equity transactions.
According to the filing dated July 1, 2026, Director and Principal Financial Officer Claudia Grimaldi acquired 2,048,378 shares of IGC Pharma common stock at $0.27 per share in exchange for the cancellation of approximately $553,062 of debt…
IGC Pharma's (NYSE American: IGC) AI Platform Cuts Alzheimer's Research by 90%, …
Image: http://www.abnewswire.com/pressreleases/wp-content/uploads/2026/06/2026
IGC Pharma, Inc. (NYSE: IGC) a clinical-stage Biotechnology company developing treatments for Alzheimer's Disease and Artificial Intelligence (AI) enabled healthcare technologies, today announced the beta release of its proprietary Agentic Harmonization Assistant ("AHA"), a patent-pending Healthcare AI platform designed to accelerate Alzheimer's Drug Discovery, Clinical Research, Precision Medicine, and Pharmaceutical Development by helping researchers quickly combine and organize Alzheimer's disease, aging-related, and other medical data that is often scattered…
IGC Pharma (NYSE American: IGC) Alzheimer's Drug Gains Attention After Ascendian …
IGC Pharma, Inc. (NYSE: IGC), a clinical-stage biotechnology company focused on Alzheimer's disease, artificial intelligence, and drug discovery, is drawing renewed investor attention after Ascendiant Capital reiterated its BUY rating and increased its 12-month price target to $5.50, citing multiple potential catalysts expected throughout 2026.
Investor interest has already begun to build. On June 9, 2026, shares of IGC Pharma reached an intraday high of $0.30 before closing at $0.285, with…
Alzheimer's AI Biotech IGC Pharma, Inc. (NYSE: IGC) Stock in Focus - More Stocks …
IGC Pharma, Inc. (NYSE: IGC) a clinical-stage biotechnology company developing AI-powered Alzheimer's disease therapies, is gaining investor attention after reporting Q1 2026 financial results and continued progress in its ongoing Phase 2 CALMA clinical trial evaluating IGC-AD1 for agitation associated with Alzheimer's dementia.
The company reported that patient enrollment in the CALMA trial recently reached approximately 80% completion, advancing toward its target enrollment of 146 patients. IGC Pharma also expanded its…
